Biodexa Pharmaceuticals Bolsa (NASDAQ: BDRX)

Últimas noticias sobre Biodexa Pharmaceuticals (NASDAQ:BDRX) Bolsa

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals PLC

BOMBARDIER 6.25% PFD A by Bombardier Inc.

Bombardier Inc

Benzinga examined the prospects for <a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener">many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
U.S. markets rebounded this week as President Donald Trump softened his stance on trade and monetary policy. He indicated that tariffs on Chinese imports could decrease from the current 145% and affirmed his support for Federal Reserve Chair Jerome Powell, alleviating investor concerns about central bank independence.
The S&amp;P 500 regained nearly 80% of its post-April 2 losses, with notable gains in technology stocks. ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) led with a 20% weekly increase, while Tesla (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NYSE">TSLA</a>) surged 9.9% after CEO Elon Musk announced a reduced focus on the Department of Government Efficiency (DOGE).
Despite the rally, economic indicators signaled caution. U.S. private sector growth slowed to a 16-month low, and consumer sentiment declined sharply. Inflation expectations rose, with one-year forecasts reaching 6.5%, the highest since 1981, suggesting persistent economic uncertainty.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.
The Bulls
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44935008/netflix-stock-nears-all-time-high-whats-going-on">"Netflix stock nears all-time high: What's going on?"</a>, by Adam Eckert, reports that Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) shares approached record highs following strong Q1 earnings—$10.54 billion in revenue and $6.61 EPS—driven by robust subscription and advertising growth, with analysts raising price targets up to $1,514 and highlighting the company's insulation from global tariffs due to its digital-only business model.
<a href="https://www.benzinga.com/general/biotech/25/04/44963467/why-is-summit-therapeutics-stock-soaring-on-wednesday">"Why Is Summit Therapeutics Stock Soaring On Wednesday?"</a>, by Vandana Singh, reports that Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares surged after partner Akeso, Inc. announced that their Phase 3 HARMONi-6 trial met its primary endpoint, with ivonescimab plus chemotherapy showing a statistically significant improvement in progression-free survival over BeiGene Ltd.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>) tislelizumab combo in patients with advanced squamous non-small cell lung cancer.
<a href="https://www.benzinga.com/general/biotech/25/04/44966369/novavaxs-covid-19-vaccine-nears-fda-full-approval-stock-jumps">"Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps"</a>, by Vandana Singh, reports that Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares rose after the company stated its Biologics License Application is approvable and awaits FDA response following a post-marketing data request.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/news/earnings/25/04/44998075/celestica-beats-q1-estimates-raises-fy-outlook-on-strengthening-demand-shares-slide">Celestica Beats Q1 Estimates, Raises FY Outlook On ‘Strengthening Demand,' Shares Slide</a>
<a href="https://www.benzinga.com/25/04/44927300/this-nvidia-backed-ai-upstart-boasts-extremely-rapid-revenue-growth-analyst-initiates-overweight">Nvidia-Backed AI Startup Boasts ‘Extremely Rapid Revenue Growth' &#8211; JPMorgan Initiates With Overweight</a>
<a href="https://www.benzinga.com/trading-ideas/movers/25/04/44995270/why-is-rocket-lab-stock-trading-higher-on-thursday">Why Is Rocket Lab Stock Trading Higher On Thursday?</a>
The Bears
<a href="https://www.benzinga.com/news/earnings/25/04/44996628/intel-q1-earnings-revenue-beat-eps-beat-shares-tumble-on-weak-guidance-chipmaker-plans-swift-actions-to-drive-efficiency">"Intel Q1 earnings: Revenue beat, EPS beat, shares tumble on weak guidance, chipmaker plans ‘swift actions' to drive efficiency"</a>, by Adam Eckert, reports that Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares fell after the company reported first-quarter revenue of $12.67 billion and adjusted earnings of 13 cents per share, both surpassing analyst expectations, but issued a disappointing second-quarter revenue forecast of $11.2–$12.4 billion, prompting CEO Lip-Bu Tan to announce organizational streamlining and cost-cutting measures to enhance efficiency.
<a href="https://www.benzinga.com/25/04/44903087/amazon-stock-downgraded-price-target-slashed-as-tariffs-create-uncertainty">"Amazon stock downgraded, price target slashed as tariffs create uncertainty"</a>, by Erica Kollmann, reports that Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares fell after Raymond James analyst Josh Beck downgraded the stock from Strong Buy to Outperform and cut the price target from $275 to $195, citing underestimated EBIT pressures from tariffs and macroeconomic headwinds.
<a href="https://www.benzinga.com/news/earnings/25/04/44966124/ibm-shares-slide-despite-better-than-expected-q1-details">"IBM Shares Slide Despite Better-Than-Expected Q1: Details"</a>, by Erica Kollmann, reports that International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) shares fell despite beating Q1 expectations with $1.60 EPS and $14.54 billion in revenue, as investors reacted to CEO Arvind Krishna's warning that economic uncertainty may cause clients to pause spending.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44962797/enphase-energy-stock-is-tumbling-wednesday-why-investors-are-selling-shares">Enphase Energy Stock Is Tumbling Wednesday: Why Investors Are Selling Shares</a>
<a href="https://www.benzinga.com/analyst-ratings/reiteration/25/04/44965222/metas-fundamentals-look-fragile-heading-into-q1-report-analyst-warns">Meta's Fundamentals Look Fragile Heading Into Q1 Report, Analyst Warns</a>
<a href="https://www.benzinga.com/news/earnings/25/04/44995935/t-mobile-shares-drop-despite-better-than-expected-q1-report-details">T-Mobile Shares Drop Despite Better-Than-Expected Q1 Report: Details</a>
Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

News

Markets

AMZN

ENPH

INTC

NFLX

NVAX

RKLB

SMMT

TMUS

TSLA

Benzinga Bulls And Bears: Netflix, Novavax, Intel — And The Market Begins To Bounce Back

Microsoft Corp. co-founder Bill Gates says he is glad that his daughter Phoebe Gates never asked him to back her business, noting that it could have complicated their relationship.
What Happened:&nbsp;In an interview <a href="https://www.nytimes.com/2025/04/24/style/phoebe-gates-bill-gates-resale-phia.html">with</a> the New York Times, Bill Gates mentioned that while he would have supported Phoebe&#8217;s business, it would have involved certain conditions that might have complicated their relationship.
"I would have kept her on a short leash and be doing business reviews, which I would have found tricky, and I probably would have been overly nice, but wondered if it was the right thing to do. Luckily, it never happened," he said.
Phoebe launched Phia on April 24, a platform that provides&nbsp;price comparisons for clothing across&nbsp;40,000 sites, aiming to offer users the best deals.
Phoebe, who&nbsp;graduated from Stanford in 2024, shared on her podcast &#8220;The Burnouts&#8221; that her father was initially hesitant about her entrepreneurial ambitions.
Dropping out of college, unlike her father, was not an option for her. Despite feeling like a &#8220;nepo baby&#8221; during her freshman year, Phoebe has&nbsp;secured over half a million&nbsp;dollars in funding from venture capitalists and angel investors, as reported by The Times.
See Also:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/45012922/trump-meme-coin-surges-15-as-organizers-clarify-participation-rules-for-gala-dinner" target="_blank" rel="noreferrer noopener">TRUMP Meme Coin Surges 15% As Organizers Clarify Participation Rules For Gala Dinner</a>
She acknowledged the advantages her family background provided but also emphasized the internal pressure she feels to succeed. Phoebe and her cofounder, Sofia Kianni, believe their business taps into a significant market, catering to young women seeking the best clothing deals online.
Why It Matters: The launch of&nbsp;Phia&nbsp;by Phoebe Gates comes at a time when her father,&nbsp;Bill Gates, has been vocal about the transformative potential of technology.
In a recent discussion, Gates predicted that&nbsp;<a href="https://www.benzinga.com/tech/25/04/44857520/bill-gates-says-his-kids-and-grandkids-will-live-in-a-very-changed-world-as-ai-puts-an-end-to-shortage-of-teachers-and-doctors">artificial intelligence</a>&nbsp;will revolutionize industries, potentially altering the future landscape for his children and grandchildren. This context highlights the importance of Phoebe&#8217;s venture, as it aligns with the broader technological shifts her father envisions.
Moreover, the Gates family has been in the spotlight due to&nbsp;<a href="https://www.benzinga.com/news/25/04/45002884/bill-gates-ex-wife-melinda-french-gates-brushes-off-criticism-from-elon-musk-and-bill-ackman-says-im-in-the-arena-doing-the-work-on-her-philanthropic-efforts">Melinda French Gates</a>&nbsp;addressing criticism from prominent figures like&nbsp;Elon Musk&nbsp;regarding her philanthropic work.
Bill Gates himself faced skepticism when he left academia to start&nbsp;Microsoft, as recounted by his former&nbsp;<a href="https://www.benzinga.com/general/entertainment/25/04/44893684/bill-gates-harvard-professor-thought-what-a-waste-when-he-left-academia-but-that-small-company-he-founded-changed-the-world">Harvard professor</a>.
Read Next:
<ul>
<li><a href="https://benzinga.com/markets/25/04/44979972/us-treasury-hits-record-15-billion-in-customs-and-excise-tax-haul-amid-trumps-trade-policies" target="_blank" rel="noreferrer noopener">US Treasury Hits Record $15 Billion In Customs And Excise Tax Haul Amid Trump&#8217;s Trade Policies</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: Alexandros Michailidis On Shutterstock.com

Tech

Bill Gates Says 'Luckily' His Daughter Phoebe Gates Never Asked Him To Back Her Business

President&nbsp;Donald Trump&#8216;s trade war with China has led to a notable decrease in U.S. imports from the Asian nation. Early shipping data reveals a significant drop, as companies scrambled to stockpile goods before tariffs increased to 145%.
What Happened: According to <a href="https://fortune.com/article/trump-trade-war-ocean-shipping-cancellations-imports-china/">Fortune</a>, the weeks following the April 9 &#8220;Liberation Day&#8221; saw ocean-shipped orders from China fall sharply. Import volumes decreased by over 10% in the week of April 7 and nearly 30% in the week of April 14.
Although the Trump administration is considering reducing some tariffs, a proposed port fee could levy up to $1.5 million per visit for Chinese vessels at U.S. ports.
The Port of Long Beach, California, reported fewer ship arrivals, supporting Project44&#8217;s data.&nbsp;Gene Seroka, executive director of&nbsp;the Port of LA, anticipated a 35% drop in arrivals within two weeks.
See Also:&nbsp;<a href="https://benzinga.com/news/events/25/04/44971154/trump-fails-to-impress-americas-young-shows-poll-as-they-still-favor-biden-only-15-think-us-on-right-track" target="_blank" rel="noreferrer noopener">Trump Fails To Impress America&#8217;s Young, Shows Poll As They Still Favor Biden — Only 15% Think US On Right Track</a>
Logistics experts caution that ongoing disruptions may lead to supply chain issues and increased consumer costs.
Dean Croke from DAT highlighted inventory management challenges amid tariff uncertainties, while Peter Sand from Xeneta emphasized the strain on global supply chains.
Why It Matters: The trade war&#8217;s impact on imports is part of a broader economic strategy by President Trump.
On April 23, Trump announced a substantial reduction in tariffs on Chinese goods, though not eliminating them entirely. He emphasized that the final tariff rate would be significantly lower than the current 145%, but not zero.
This stance was reiterated on April 25, when Trump, aboard Air Force One, stated that tariffs would remain unless China made substantial concessions. He stressed the importance of &#8220;opening China&#8221; for American businesses, causing market fluctuations.
Meanwhile, <a href="https://www.benzinga.com/25/04/45003278/flexport-ceo-joins-galloway-tariff-workarounds-and-fraud-will-force-trump-to-walk-back-on-trade-war-with-china">Flexport CEO Ryan Petersen</a> predicted that the U.S. might eventually &#8220;blink&#8221; in the trade standoff, as the market finds ways around tariffs. He noted differing perceptions of the conflict between the two countries, with Americans viewing it as a domestic issue and the Chinese seeing it as a foreign imposition.
Read Next:
<ul>
<li><a href="https://benzinga.com/25/04/45026565/trump-signals-possible-support-for-millionaires-tax-amid-election-concerns-recalls-george-bushs-promise-he-said-r" target="_blank" rel="noreferrer noopener">Trump Signals Possible Support For Millionaires Tax Amid Election Concerns, Recalls George Bush&#8217;s Promise: &#8216;He Said Read My Lips And&#8230; Lost An Election&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Politics

Global

Economics

Trump's Trade War Causes Sharp Decline In US Imports From China

On Friday, Cathie Wood-led Ark Invest made several significant trades. The most prominent among these involved the buying and selling of shares in Intellia Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Veracyte Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>), Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>), and UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>).
The NTLA Trade: Ark Invest&#8217;s ARK Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>) fund purchased 65,958 shares of Intellia Therapeutics. The shares were bought at a closing price of $8.31, making the total value of the trade approximately $548,136.78. This move comes amidst a 1.59% increase in NTLA&#8217;s stock price.
The META Trade: The ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>) fund sold 1,255 shares of Meta Platforms at a closing price of $547.27. The total value of this sale was approximately $686,324.85. This trade was executed as META&#8217;s stock price saw a 2.65% increase.
The VCYT Trade: Ark Invest&#8217;s ARKK fund sold 66,135 shares of Veracyte. The shares were sold at a closing price of $32.23, making the total value of the trade approximately $2,131,151.05. This sale was made as VCYT&#8217;s stock price experienced a slight increase of 0.28%.
The SYM Trade: ARK Next Generation Internet ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) fund bought 8,140 shares of Symbotic at a closing price of $21.93. The total value of this purchase was approximately $178,410.20. This purchase was made despite SYM&#8217;s stock price seeing a decrease of 0.59%.
The BIDU Trade: The ARKQ fund also bought 925 shares of Baidu at a closing price of $90.74. The total value of this purchase was approximately $83,934.50. This trade was executed as BIDU&#8217;s stock price saw a 1.39% increase.
The PATH Trade: Ark&#8217;s ARKW fund sold 984 shares of UiPath at a closing price of $11.59. The total value of this sale was approximately $11,402.56. This sale was made as PATH&#8217;s stock price experienced a 2.39% increase.
Read Next:
<ul>
<li><a href="https://benzinga.com/markets/equities/25/04/45001882/jim-cramer-stays-bullish-on-data-centers-says-if-trump-tariffs-eases-these-ai-stocks-will-fly-ag">Jim Cramer Stays Bullish On Data Centers, Says If Trump Tariffs Eases, These AI Stocks &#8216;Will Fly Again&#8217; Despite Wall Street Doubts</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Equities

ETFs

ARKK

ARKQ

BIDU

NTLA

PATH

VCYT

Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms

Hedge fund billionaire Bill Ackman's <a href="https://www.benzinga.com/top-stories/24/07/40038840/bill-ackman-lost-400m-on-netflix-shares-in-2022-how-much-would-the-billionaire-investor-have-if-he-d">decision to sell his</a> Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) shares during a rough patch in 2022 has become one of the most high-profile missed opportunities today.
What Happened: In January 2022, Ackman revealed that his hedge fund, Pershing Square Capital Management, had purchased more than $1 billion worth of Netflix stock—about 3.1 million shares—when it was trading around $400.
The move came after Netflix stock had fallen more than 65% amid concerns over slowing growth and a tech-sector sell-off. However, the bet soured quickly.
By April, Netflix's stock plummeted further following a disappointing earnings report and investor uncertainty surrounding its ad-based subscription plans.
See Also: <a href="https://www.benzinga.com/general/entertainment/25/04/44995039/netflix-ceo-says-streaming-company-saved-hollywood-as-stock-hits-new-all-time-highs">Netflix CEO Says Streaming Company &#8216;Saved Hollywood&#8217; As Stock Hits New All-Time Highs</a>
Ackman exited the position just three months later, when shares were trading near $225, taking a loss of approximately 40%. In total, Pershing Square's short-lived Netflix investment cost the firm an estimated $400 million.
At the time, the sale seemed prudent. Netflix's stock continued to slide, bottoming out near $175 in the following months. But in a surprising turn, both the broader tech sector and Netflix rebounded sharply. As of today, Netflix shares are trading around $1,096.87—a stunning recovery of over 168.085% from Ackman's highest estimated buy-in.
Had Ackman held onto the position, those 3.1 million shares would now be worth nearly $3.4 billion, turning a brief misstep into one of his most lucrative trades ever.
Why It's Important: Last week, Netflix Co-CEO Greg Peters reassured investors that <a href="https://www.benzinga.com/25/04/44881044/netflix-downplays-recession-fears-amid-market-volatility-triggered-by-trump-tariffs-co-ceo-greg-peters-raves-about-resilient-799-ad-plan-we-havent-seen-any-significant-changes">the company remains confident</a>, even amid market turbulence and growing recession fears driven by new tariffs.
He went on to say that entertainment has traditionally remained strong during economic downturns, and Netflix continues to see that pattern hold.
Co-CEO Ted Sarandos added that the company is staying focused on factors within its control, stating, "We're not changing anything in the forecast."
For the first quarter, <a href="https://www.benzinga.com/general/entertainment/25/04/44877995/netflix-crushes-q1-says-its-working-hard-to-improve-and-expand-its-offering">Netflix reported revenue of $10.54 billion</a>—a 12.5% year-over-year increase—slightly beating Wall Street's estimate of $10.52 billion.
Global markets have seen heightened volatility in response to <a href="https://www.benzinga.com/media/25/04/44657800/trumps-tariffs-stir-global-markets-wall-street-loses-2-trillion-and-more-this-week-in-economics">new trade tariffs introduced</a> by President Donald Trump. The S&amp;P 500 is down by 6.54% year-to-date while the Nasdaq-100 has slipped 8.40% during the same period.
Price Action: Netflix shares are up 23.70% year-to-date and have soared 94.21% over the past 12 months, according to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0417">Benzinga Pro</a>.
The streaming giant holds a growth score of 69.79% and a momentum rating of 95.93, based on Benzinga Edge Stock Rankings. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Click here to see how it compares to other</a> leading entertainment and tech companies.
Netflix currently has a consensus price target of $1,082.97 from 32 analysts, with the highest target of $1,514 issued by Rosenblatt on April 21. Recent ratings from Evercore ISI Group, Macquarie, and Wedbush point to an average target of $1,183.33, suggesting an 8.17% potential upside.
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/NFLX/analyst-ratings"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25053540/Screenshot-2025-04-25-at-3.05.31%E2%80%AFPM-1024x368.png" alt="" class="wp-image-888372" style="width:920px;height:auto" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/44806071/netflix-eyes-1-trillion-market-cap-by-2030-aims-to-double-revenue-and-dominate-global-streaming-report">Netflix Eyes $1 Trillion Market Cap By 2030, Aims To Double Revenue And Dominate Global Streaming: Report</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Entertainment

Bill Ackman Missed Out On $3.4 Billion Payday By Selling Netflix Stock Before The Boom: NFLX Now Seen As A Recession Play

In an interview published Friday, President Donald Trump expressed openness to a tax increase on millionaires, despite previous opposition. He noted that his main concern is the potential impact on his electoral prospects.
What Happened: In an interview <a href="https://time.com/7280106/trump-interview-100-days-2025/">with</a> Time magazine, Trump referenced former President George H.W. Bush, who lost re-election after breaking a no-tax promise, as a cautionary tale.
Trump stated, "I saw Bush where they said, where he said ‘Read my lips' and he lost an election."
Meanwhile, Trump&#8217;s advisors are reportedly debating whether to back a tax hike on those earning over $1 million annually, part of the GOP&#8217;s 2025 tax plan. Trump and House Speaker Mike Johnson (R-La.) have expressed concerns about millionaires leaving the country if taxes rise.
See Also: <a href="https://benzinga.com/news/events/25/04/44971154/trump-fails-to-impress-americas-young-shows-poll-as-they-still-favor-biden-only-15-think-us-on-right-track">Trump Fails To Impress America&#8217;s Young, Shows Poll As They Still Favor Biden — Only 15% Think US On Right Track</a>
Despite these concerns, Trump said he&#8217;d be &#8220;honored&#8221; to pay more taxes, provided it doesn&#8217;t jeopardize his election chances.
He emphasized the importance of supporting the middle class, saying, "I'd be raising [taxes] on wealthy to take care of middle class."
Opposition from Trump&#8217;s allies, including Newt Gingrich, Steve Moore, and Larry Kudlow, highlights the internal GOP debate on the issue. They argue the plan contradicts Trump&#8217;s tax-cut promises.
Why It Matters: The potential shift in Trump&#8217;s tax stance is significant given his previous economic policies. Recently, Trump proposed replacing federal income taxes with revenue from tariffs, a move criticized by economists for its feasibility.
In an <a href="https://www.benzinga.com/markets/25/04/44944580/trump-says-tariffs-could-replace-income-tax-experts-warn-the-math-doesnt-work">interview</a> on April 15, he suggested tariffs could generate enough revenue to eliminate personal income taxes.
This idea has led to market volatility, with investors uncertain about the implications of such tariffs. Finance expert Ramit Sethi cautioned against making hasty decisions based on these announcements, emphasizing the potential financial risks involved.
The <a href="https://www.benzinga.com/personal-finance/25/04/44852424/you-could-literally-cost-yourself-millions-finance-expert-warns-against-panic-decision-on-trump-tariffs">advice</a> comes amid rising interest in foreign trade zones (FTZs) as companies seek to mitigate tariff impacts. U.S. firms have <a href="https://www.benzinga.com/government/regulations/25/04/44918012/trump-tariffs-drive-companies-to-stash-imports-in-tax-free-foreign-trade-zones">increasingly turned</a> to FTZs to defer or reduce duty payments.
Read Next:
<ul>
<li><a href="https://benzinga.com/news/25/04/44972159/trump-tower-becomes-flashpoint-for-earth-day-protest-as-activist-defaces-seal-slams-kamala-harris-fracked-ga">Trump Tower Becomes Flashpoint For Earth Day Protest As Activist Defaces Seal, Slams Kamala Harris&#8217; &#8216;Fracked Gas&#8217; Climate Stance</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Jonah Elkowitz

Trump Signals Possible Support For Millionaires Tax Amid Election Concerns, Recalls George Bush's Promise: 'He Said Read My Lips And… Lost An Election'

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), a biopharmaceutical company, is engaged in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.
It will report its Q1 2025 earnings on April 25, before the market opens. Wall Street analysts expect the company to post EPS of $2.51, up from $2.31 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $12.91 billion, up from $12.31 billion a year earlier.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
The 52-week range of AbbVie stock price was $153.58 to $218.66.
AbbVie's dividend yield is 3.86%. It paid $6.56 per share in dividends during the last 12 months.
<h2 class="wp-block-heading">The Latest On AbbVie</h2>
On Jan. 31, the company announced its Q4 2024 earnings, posting adjusted EPS of $2.16, beating the street view of $2.11, as reported by <a href="https://www.benzinga.com/news/earnings/25/01/43392796/abbvie-jumps-after-q4-earnings-beat-skyrizi-and-rinvoq-boom-offsets-humira-decline">Benzinga</a>. Quarterly sales came in at $15.102 billion, outpacing the analyst consensus estimate of $14.827 billion.&nbsp;
AbbVie sees full-year 2025 adjusted EPS in the range of $12.12 to $12.32, compared to the street view of $12.18. The company reaffirmed its expectations for a high single-digit compound annual revenue growth rate through 2029.
Check out this <a href="https://www.benzinga.com/insights/analyst-ratings/25/03/44128338/13-analysts-have-this-to-say-about-abbvie">article by Benzinga</a> for 13 analysts' insights on AbbVie.
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
<h2 class="wp-block-heading">How Can You Earn $100 Per Month As An AbbVie Investor?</h2>
If you want to make $100 per month — $1,200 annually — from AbbVie dividends, your investment value needs to be approximately $31,088, which is around 183 shares at $170.16 each.&nbsp;
Understanding the dividend yield calculations: When making an estimate, you need two key variables — the desired annual income ($1,200) and the dividend yield (3.86% in this case). So, $1,200 / 0.0386 = $31,088 to generate an income of $100 per month.
You can calculate the dividend yield by dividing the annual dividend payments by the current price of the stock.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
The dividend yield can change over time. This is the outcome of fluctuating stock prices and dividend payments on a rolling basis.
For instance, assume a stock that pays $2 as an annual dividend is priced at $50. Its dividend yield would be $2/$50 = 4%. If the stock price rises to $60, the dividend yield drops to 3.33% ($2/$60). A drop in stock price to $40 will have an inverse effect and increase the dividend yield to 5% ($2/$40).
In summary, income-focused investors may find AbbVie stock an attractive option for making a steady income of $100 per month by owning 183 shares of stock.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

ABBV

How Much Would It Take To Earn $100 A Month From AbbVie Stock

A 25% tariff on imported cars is revving up the pressure on European luxury automakers, and high-end buyers in the U.S. could face five-figure price hikes, according to Tim Urquhart, principal automotive analyst at S&amp;P Global Mobility.
President Donald Trump said on April 10 that his administration would enforce a 25% tariff on imported vehicles as part of his broader &#8220;reciprocal trade&#8221; policy, though he has since suggested he may delay the move.
While some tariffs were delayed for 90 days, this particular levy stayed in place — and it&#8217;s hitting the ultra-luxury market hard.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
<h2 class="wp-block-heading">Ferrari Raises Prices as Other Brands Scramble</h2>
Ferrari <a href="https://www.ferrari.com/en-EN/corporate/articles/ferrari-commercial-policy-update">announced</a> last month that it would increase the prices of nearly all of its models sold in the U.S. by up to 10%. The hike applies even to vehicles ordered months prior, including the newly released Purosangue SUV and the 12 Cilindri grand tourer built in Maranello, Italy.
Urquhart told <a href="https://www.businessinsider.com/trumps-tariffs-threaten-us-love-affair-with-european-luxury-cars-2025-4">Business Insider</a>, "It&#8217;s very bad news. There&#8217;s no getting around that. Ferrari, Bentley, and Rolls-Royce are in a tough spot — they can't absorb a 25% tariff, so that will have to be passed on to customers."
Urquhart added that ultra-luxury brands have more pricing flexibility than mass-market automakers due to their premium sticker prices.
Rolls-Royce, a subsidiary of BMW, is still assessing the situation. <a href="https://www.theguardian.com/business/2025/mar/19/bentley-could-pass-costs-of-us-tariffs-to-buyers-due-to-drop-in-chinese-demand">Bentley</a>, owned by Volkswagen AG, will continue U.S. imports but hasn&#8217;t decided on pricing adjustments.&nbsp;
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
<h2 class="wp-block-heading">Audi, Jaguar, And Mercedes Adjust U.S. Strategies</h2>
Other European automakers are adjusting quickly. <a href="https://media.jaguarlandrover.com/news/2025/04/jlrs-statement-tariffs">Jaguar Land Rover</a> — owned by India's Tata Motors — temporarily halted U.S. shipments to evaluate the impact.&nbsp;
Audi, a Volkswagen subsidiary, was holding deliveries at U.S. ports as it weighed the next steps, according to <a href="https://www.autonews.com/volkswagen/audi/an-trump-tariffs-audi-holds-inventory-0403/">Automotive News</a>.
Mercedes-Benz is also reevaluating its lower-end lineup. As reported by<a href="https://www.bloomberg.com/news/articles/2025-04-01/mercedes-weighs-pulling-us-entry-level-cars-over-trump-tariffs"> Bloomberg</a>, Mercedes may pull some of its entry-level models from the U.S. market due to profitability concerns.
While several automakers posted strong sales gains in March, <a href="https://newsroom.porsche.com/en_US/2025/company/Q1-PCNA-Sales-39125.html">Porsche</a> reported its best-ever first quarter in the U.S., with Q1 2025 sales jumping 40.6%. The company credited strong demand for the 911 and Macan models for the record growth.&nbsp;
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
<h2 class="wp-block-heading">Tariffs Create Long-Term Headaches</h2>
The broader economic fallout could be steep. A report by<a href="https://www.andersoneconomicgroup.com/tariffs-economic-impact-on-auto-industry/"> Anderson Economic Group</a> estimated that U.S. consumers could pay over $30 billion in added costs from the tariffs in the first year alone. The report also mentioned that the average imported vehicle price could climb by $2,500 to $5,000, with ultra-luxury models rising even more.
Strategy and insight director at Cox Automotive, Philip Nothard, told<a href="https://www.businessinsider.com/trumps-tariffs-threaten-us-love-affair-with-european-luxury-cars-2025-4"> Business Insider</a> that shifting production to the U.S. to bypass tariffs would be slow and costly. "You can't just suddenly set up production plants, supply chain, and labor overnight," he said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Ferrari, Rolls-Royce, And Bentley Prices Are About To Soar As 25% Tariff Sends Shockwaves Through U.S. Luxury Car Market

XFOR

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

STSSW

STSS

NAAS

STKH

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 20 years by 6.35% on an annualized basis producing an average annual return of 14.42%. Currently, Eli Lilly has a market capitalization of $797.04 billion. 
Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 20 years ago, it would be worth $15,015.11 today based on a price of $887.40 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745624717_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) has outperformed the market over the past 10 years by 7.94% on an annualized basis producing an average annual return of 18.14%. Currently, Live Nation Entertainment has a market capitalization of $30.51 billion. 
Buying $100 In LYV: If an investor had bought $100 of LYV stock 10 years ago, it would be worth $517.99 today based on a price of $132.00 for LYV at the time of writing.
<h3>Live Nation Entertainment's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745623811_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Morningstar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORN#NASDAQ">MORN</a>) has outperformed the market over the past 20 years by 24.47% on an annualized basis producing an average annual return of 32.54%. Currently, Morningstar has a market capitalization of $12.00 billion. 
Buying $100 In MORN: If an investor had bought $100 of MORN stock 20 years ago, it would be worth $27,993.02 today based on a price of $280.63 for MORN at the time of writing.
<h3>Morningstar's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745622912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MORN

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Grant Cardone does everything he can to minimize his income taxes. The real estate investor and bestselling author moved to Florida to avoid state income taxes, and he also uses various assets to minimize his federal income taxes.
Cardone recently laid out the playbook for reducing your taxable income on paper to keep more of what you earn. However, he started right out of the gate by telling people what they shouldn't do with their money.
"If you can't write it off, don't buy it," Cardone stated in an <a href="https://x.com/GrantCardone/status/1913579678729744714">X post</a>.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
Anyone can use these strategies to trim their tax burden. While there are more tax-saving tactics you can use if you speak with a professional, Cardone's post offers a head start.
<h2 class="wp-block-heading">Invest In Real Assets And Claim Depreciation&nbsp;</h2>
Cardone's first tip for lowering your taxes was to invest in real assets and claim depreciation. It makes sense that this tip would be on the top of Cardone's list. He has a $5 billion real estate portfolio and regularly looks for new deals.
Real estate investors can use depreciation to artificially reduce their taxable income. However, it gets even better for investors who regularly buy properties and use Section 179 of the tax code. This part of the tax code allows an investor to write off an entire property's value in one year. For instance, if an investor earns $1 million and buys a $1.5 million property, they can show a $500,000 net loss when they report to the IRS.
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
You have to fulfill certain conditions to be eligible for Section 179 of the tax code. However, if you're eligible, you can save a lot of money while investing in real assets. This tax strategy also works with any vehicle that is more than 6,000 pounds.
<h2 class="wp-block-heading">Buy, Borrow, Die</h2>
Cardone is a fan of the "Buy, Borrow, Die" model, which involves borrowing against assets instead of selling them. Assets can gain value over time, especially inflation hedges like real estate. If you borrow against these assets instead of selling them, you don't have to pay any capital gains taxes. Furthermore, you still get to benefit from any cash flow and appreciation.
As your net worth grows, you get to borrow cash at lower interest rates. Billionaires get lower interest rates than most people because they are the banks' largest customers. As you grow wealth, it becomes cheaper to borrow money. You can gradually pay back debt and still get to keep your assets when it's all said and done.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
<h2 class="wp-block-heading">Set Up A Home Office</h2>
Business owners and side hustlers can set up home offices and deduct it for tax purposes. It's extra money that the IRS is willing to let you keep as long as you have the right documentation.
Finally, if you're going the business route, you might as well put your kids on payroll. Cardone recommends this strategy because your kids will receive a lower tax rate than you would at your highest dollar. Your children can also take advantage of the standard tax deduction to further reduce how much they pay. Meanwhile, it will show up in your finances as a business expense, which will reduce your taxable income.
Most parents want to give their children inheritances anyway. Setting them up as business employees allows you to give them the money without the government taking some of it away. You also end up with a lower tax bill.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Grant Cardone Reveals How Anyone Can Lower Their Tax Bill: 'If You Can't Write It Off, Don't Buy It'

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) has outperformed the market over the past 10 years by 18.46% on an annualized basis producing an average annual return of 28.66%. Currently, Corcept Therapeutics has a market capitalization of $7.52 billion. 
Buying $1000 In CORT: If an investor had bought $1000 of CORT stock 10 years ago, it would be worth $11,852.89 today based on a price of $71.25 for CORT at the time of writing.
<h3>Corcept Therapeutics's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745622011_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CORT

Here's How Much $1000 Invested In Corcept Therapeutics 10 Years Ago Would Be Worth Today

Modine Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) has outperformed the market over the past 15 years by 1.48% on an annualized basis producing an average annual return of 12.15%. Currently, Modine Manufacturing has a market capitalization of $4.27 billion. 
Buying $1000 In MOD: If an investor had bought $1000 of MOD stock 15 years ago, it would be worth $5,790.86 today based on a price of $81.13 for MOD at the time of writing.
<h3>Modine Manufacturing's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745621111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Shaquille O'Neal's life isn't divided by status—it's defined by impact. One minute he's fielding calls from billionaires, the next he's helping a <a href="https://www.benzinga.com/personal-finance/25/01/42953411/nba-star-shaq-learned-true-meaning-of-pressure-after-his-dad-took-him-to-a-homeless-family-he-paid-36000-to-get-them-off-the-streets">homeless family get an apartment</a>.&nbsp;
In 2017, he announced plans to run for sheriff in 2020 to <a href="https://youtu.be/GlhvMjeSg-c?si=hH1qoWxL2ECl8ZUU">WXIA-TV Atlanta</a>, stating, "This is not about politics. This is about bringing people closer together." Though he never officially filed, the sentiment reflected his lifelong commitment to community and connection.
"I'm a guy that speaks all languages," Shaq explained. "I can put on a suit and have a conversation with Bill Gates. I can go in the hood and talk to the homies, and talk to the children."
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
This philosophy has guided his ventures beyond basketball. A chance encounter at a hotel led to an early investment in Google. While dining at the Four Seasons, <a href="https://www.benzinga.com/personal-finance/24/10/41432168/nba-icon-shaquille-oneal-says-an-accidental-babysitting-gig-led-to-his-early-investment-in-googl">Shaq played with some children</a> whose father, impressed by his demeanor, offered him an investment opportunity in a then-little-known company called Google. Shaq invested and later remarked on "The Ellen DeGeneres Show," "I got a really big return."&nbsp;
His investment strategy was influenced by <a href="https://www.benzinga.com/personal-finance/25/03/44068159/nba-legend-shaq-says-his-net-worth-quadrupled-once-he-took-note-from-jeff-bezos-and-started-investing-in-things-that-change-peoples-lives">Jeff Bezos's advice to invest in things that change people's lives</a>. This approach led Shaq to invest in companies like Ring and Lyft, leveraging his celebrity status to gain early access to promising ventures.&nbsp;
However, not all his business decisions were hits. He passed on investing in Starbucks, believing at the time that "Black people don't drink coffee." He later admitted this was one of his biggest business regrets.
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
Shaq's commitment to authenticity is evident in his business choices. He sold his <a href="https://www.benzinga.com/startups/24/12/42468734/nba-legend-shaq-owned-17-auntie-annes-franchises-but-sold-them-after-realizing-black-people-dont-like-pretzels-that-much">17 Auntie Anne's pretzel franchises</a>, explaining on the "<a href="https://youtu.be/XByJpQzl2DY?si=-dFFd6BsJFCji1ot">Earn Your Leisure Podcast</a>," "Black people don't like pretzels that much. So I had to switch it up."
But the missteps don't outshine the bigger picture. He buys laptops for kids he just met. Pays for strangers' funerals. Picks up the tab for young fans <a href="https://www.benzinga.com/personal-finance/25/01/43077262/nba-legend-shaq-spotted-a-young-man-buying-an-engagement-ring-in-zales-when-he-swooped-in-and-paid-for-it-tell-your-girlfriend-i-got-it">buying engagement rings</a>. And he never posts about it—he lets the people on the receiving end do the talking.
In 2021, his <a href="https://www.benzinga.com/personal-finance/25/03/44207096/shaq-said-his-krispy-kreme-store-was-likely-burned-down-by-homeless-trying-to-stay-warm-im-not-gonna-be-putting-charges-on-homeless-people">Krispy Kreme store in Atlanta was destroyed by fire</a> for a second time, Shaq didn't flinch. Authorities believed homeless individuals had started the blaze trying to stay warm. He chose not to press charges.
Shaq may not have become sheriff like he once hoped, <a href="https://www.benzinga.com/personal-finance/25/03/44380108/trust-me-im-reading-what-hes-doing-every-day-nba-legend-shaq-with-a-500-million-net-worth-swears-by-warren-buffetts-investing-wisdom">but with a $500 million net worth</a> and a reputation built on real connection, he hardly needed the badge. When he says he can talk business with Gates and friends from the "hood"—he means it. And that range? That's not a gimmick. It's why people trust him, invest with him, and invite him into conversations that actually move things forward.
Read Next:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.</li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>
Photo: Shutterstock

NBA Legend Shaq Says He Can 'Throw On a Suit And Have A Conversation With Bill Gates' Then Head to the Hood and Talk to the 'Homies'

Press Releases

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Legal

Biodexa Announces Allowance of U.S. Patent Covering  Oral Rapamycin Nanoparticle Preparations ("eRapa") and Use

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Health Care

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Preliminary Results for the Year Ended 31 December 2024

Notice of General Meeting

AEMD

ANPCY

ASPI

ATWT

BDRX

BENF

BIXT

BNRG

BOSC

CSE:HG

ELRRF

GOSS

GOVX

HDRSF

HGRAF

IMRN

IPWR

JAGX

LGVN

MESO

PBEGF

RGBP

SIGY

TSX:CNL

TSX:ELO

TSX:TXP

TSXV:HI

TSXV:WRLG

UCAR

USEG

WRLGF

XXII

Aditxt

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Alzamend Neuro

180 Life Sciences

Azitra

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Galecto

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

NuCana

Oragenics

Palisade Bio

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Theriva Biologics

VivoSim Labs

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

Xenetic Biosciences

Ladenburg Thalmann

Screenshot 2025-03-18 at 8.36.36 PM

Biotech

General

Fast Track Designation Secured, Successful Protocol Discussion With FDA And CROs Confirmed, Biodexa On Track To Initiate Funded Phase 3 FAP Trial Next Quarter

Untitled design - 2025-02-11T232646.924

Following Positive Phase 2 Results And Orphan Drug Designation, Biodexa&#39;s FAP Drug Receives FDA Fast Track Status

Image

Gaining Momentum, Biodexa Is Advancing Two Recent Acquisitions Through The Clinic

Untitled design - 2024-10-16T235234.675

Biodexa&#39;s MX-110 Continues To Show Promise In Recurrent Glioblastoma (rGBM), The Deadliest Brain Cancer

Screenshot 2024-07-10 at 9.15.35 PM

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa In Treatment Of Precancerous Polyps In The GI Tract – Now 12-Month Data

Screenshot 2024-06-03 at 5.21.04 PM

Promising Phase 2 Results For Biodexa&#39;s eRapa™ Indicates Hope For FAP Patients Who Otherwise Have A 100% Lifetime Risk Of Colorectal Cancer

Screenshot 2024-05-08 at 7.48.00 PM

Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition

Untitled design - 2024-03-28T172702.605

Biodexa&#39;s MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Redington 2_29

PowerShares Dynamic Financial Sector Portfolio

Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone

Comments

Biodexa Pharmaceuticals

Noticias

Últimas noticias sobre Biodexa Pharmaceuticals (NASDAQ:BDRX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL